Edoxaban
Stroke prevention in non-valvular atrial fibrillation; treatment of DVT and pulmonary embolism
- CAS No.
- 480449-70-5
- Indication Class
- Cardiovascular / Renal
- Patent Expiry
- Expiring within 2 yrs · 2027 (indicative)
- Therapeutic Area
- Cardiovascular / Anticoagulation
- Target / Mechanism
- F10
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
- Patent Scope
- EU major markets; US later — verify per target country
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A next-generation oral anticoagulant (DOAC) clearly replacing warfarin, with a huge atrial-fibrillation population on chronic therapy, a clearly definable blockbuster.
Cardiovascular / Anticoagulation · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Edoxaban is a prescription oral anticoagulant (blood thinner) used to prevent and treat serious blood clots.
Supply source: Unibest · Edoxaban, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.